Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential
Management Reshuffle And 20% Headcount Cut
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
You may also be interested in...
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.